Inhibitor treatment of AML CD34+ cells in vitro showed decreased levels of JAK2 and STAT3/5 activity and reduced AML CD34+ cell proliferation and survival, but it did not affect normal CD34+ cells[94]. This evidence concerns the gene JAK2 and acute myeloid leukemia.